Cytosorbents Corporation
CTSO Healthcare Medical Devices
Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 333.3%, free cash flow grew 64.9% and total debt rose 19.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CTSO
Cytosorbents Corporation (CTSO) EV/Sales
As of 16 October 2026, Cytosorbents Corporation (CTSO) trades at a EV/Sales of 0.7×. Over the past ten years it has ranged from 0.6× (October 2026) to 1,045× (March 2015); the current reading is higher than 0% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | (12.38%) |
| FY2024 | 1.6× | 30.33% |
| FY2023 | 1.2× | (30.66%) |
| FY2022 | 1.8× | (45.95%) |
| FY2021 | 3.3× | (43.02%) |
| FY2020 | 5.8× | 14.49% |
| FY2019 | 5.1× | (51.42%) |
| FY2018 | 10.5× | (8.53%) |
| FY2017 | 11.5× | (23.88%) |
| FY2016 | 15.0× | (45.30%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | (23.82%) |
| Mar 2026 | 1.3× | (9.88%) |
| Dec 2025 | 1.4× | (22.86%) |
| Sep 2025 | 1.8× | (23.35%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AEMD Aethlon Medical, Inc. compare | −2.8× |
| TNON Tenon Medical, Inc. compare | −0.1× |
| RBOT Vicarious Surgical Inc. compare | n/m |
| NMTC NeuroOne Medical Technologies Corporation compare | 0.7× |
| CTSO Cytosorbents Corporation | 0.7× |
| BMRA Biomerica, Inc. compare | 0.9× |
| BTCY Biotricity Inc. compare | 1.7× |
| SINT SINTX TECHNOLOGIES, INC. compare | 3.7× |
| PETV PetVivo Holdings, Inc. compare | 23.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)